Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Harnessing the Power of UV Light for Virus Protection

The world is currently facing a probable epidemic related to the coronavirus. According to the Centers for Disease Control and Prevention (CDC), coronavirus (COVID-19) spreads just as other viruses do from person-to-person, mostly through respiratory droplets that occur when an infected individual sneezes or coughs. The world is on hyper-alert for ways to mitigate its spread, and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The world is currently facing a probable epidemic related to the coronavirus. According to the Centers for Disease Control and Prevention (CDC), coronavirus (COVID-19) spreads just as other viruses do from person-to-person, mostly through respiratory droplets that occur when an infected individual sneezes or coughs.

The world is on hyper-alert for ways to mitigate its spread, and one proven way to destroy viruses is via ultraviolet (UV) light, which may be a good option for a variety of scenarios.

UV Light Is an Effective Tool to Stop the Spread of Viruses

Much research has been completed on destroying viruses and germs. A certain spectrum of UV light—UVC—has been proven to kill airborne viruses, and it does so in a manner that presents no risk to humans. UVC refers to ultraviolet light with wavelengths between 200 – 280 nanometers (nm). A study conducted by a group of scientists found that UVC had the ability to kill flu viruses when placed in germ-sensitive places like hospitals, airports and schools.

While the coronavirus is different than the flu, it’s similar in nature. UVC is stealthy enough to destroy viruses.

The CDC also sponsored a study about the impact of UVC by using it in hospital patient rooms. The conclusions drawn from the researchers’ data confirmed that UVC-emitting devices could decrease the “bioburden of important pathogens in real-world settings.”

Introducing UV Light into HVAC Airflow and Ventilation Systems

Each day, you and your family venture out into the public domain and have a high probability of encountering germs and viruses. You probably already practice good hygiene to reduce these chances, such as thorough handwashing or use of hand sanitizer, but the threat remains.

Being able to harness the power of UVC light can make all the difference in stopping the spread and multiplication of these germs and viruses.

By introducing UV light into your airflow and ventilation systems, you’ll be better prepared to protect yourself from them.

Leveraging UV Light into Your Spaces with Field Controls

Integrating UV light into your home doesn’t require scientific expertise or a huge investment.

The Field Controls UV-Aire UV-16 unit has been designed to emit strong UVC band light through your heating or air conditioning system, sterilizing and reducing airborne microorganisms. It works to neutralize the organism’s DNA so that it can no longer replicate. As new indoor air circulates through your system, it’s being passed through the UV light, effectively treating it.

Field Controls completed multiple independent lab tests to verify its effect on viruses and germs, finding that it reduced test bacteria by 90% within 30 minutes. While the technology is highly advanced, it’s extremely simple to install. They require minimal maintenance, and you don’t need extensive training to use the products in your home.

Experience Added Protection with the UV-Aire UV-16

Doing all you can to safeguard from the coronavirus and other airborne pathogens is vital, and you can effectively do so with the UV-Aire UV-16.

Learn more about how it works and how it can deliver a healthier space today.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Scan.com’s $220M round makes imaging an API contract for plans and employers

Scan.com’s $220M round makes imaging an API contract for plans and employers

Scan.com closed $220 million in equity and debt. It’s expanding its U.S. imaging network plus API-based scheduling and results delivery. For health plans and employers, imaging is starting to look like a platform procurement and integration decision, not a directory problem.

  • 01If imaging access is bought via an API, the real spec becomes integration depth: two-way scheduling plus results routing into the EMR, according to Business Wire.
  • 02Scan.com’s mix of $90M equity and $130M debt earmarked for M&A and working capital points to a fast-changing imaging provider network, which can help access but demands discipline in contracting and integration testing.
  • 03The same week’s funding news for Elucid ($55M) suggests AI imaging vendors will keep pushing toward FDA-cleared workflow insertions, a different buying path than network-layer platforms.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512